Sign Up
Stories
Biosimilar Breakthrough: Simlandi FDA Approval
Share
Healthcare Innovations: Breakthroughs an...
Immunotherapy and Fungal Infection Treat...
AI-Powered Antigen Research Partnership
ANJESO Drug Insight and Market Forecast
Advancements in Antibodies to Protect Im...
Overview
API
Teva and Alvotech secure FDA approval for their biosimilar, Simlandi, an interchangeable high-concentration, citrate-free alternative to AbbVie's Humira, aiming to expand biosimilar availability in the U.S. market. The partnership plans to leverage a strategic marketing approach for the upcoming launch.
Ask a question
How might the approval of Simlandi impact the market dominance of Humira and other biologic treatments?
In what ways could the availability of high-concentration, citrate-free biosimilars like Simlandi influence healthcare costs and patient access?
What challenges could Teva and Alvotech face in establishing Simlandi's presence amidst existing biosimilar competition?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Feb 2024
Coverage
fierc